Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | Emerging monoclonal antibodies for lymphoma therapy

Thomas Kipps • 12 Nov 2015
iwNHL 2015
Non-Hodgkin Lymphoma Antibodies Ibrutinib Obinutuzumab Ofatumumab Rituximab Venetoclax

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Thomas J. Kipps, MD, PhD, of the University of California, San Diego, San Diego, CA, discusses novel monoclonal antibodies against CD20, including rituximab, ofatumumab and obinutuzumab, that are progressing in clinical development as single agents and in combination for the treatment of patients with non-Hodgkin lymphoma.

More from Thomas Kipps

Targeting ROR1 and ROR2 for the treatment of CLL and other B-cell malignancies
3:02
Targeting ROR1 and ROR2 for the treatment of CLL and other B-cell malignancies
Thomas Kipps • 5 Dec 2025
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib
3:37
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib
Thomas Kipps • 5 Dec 2025
Overcoming challenges with targeted therapies for CLL: high-risk mutations and BTKi resistance
3:09
Overcoming challenges with targeted therapies for CLL: high-risk mutations and BTKi resistance
Thomas Kipps • 6 Sep 2024
Genetic testing to risk stratify patients with CLL and aid in treatment decisions
2:11
Genetic testing to risk stratify patients with CLL and aid in treatment decisions
Thomas Kipps • 6 Sep 2024

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals